english.prescrire.org > Spotlight > 100 most recent > Anifrolumab (Saphnelo°) in systemic lupus erythematosus after failure of standard therapy

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Anifrolumab (Saphnelo°) in systemic lupus erythematosus after failure of standard therapy

 Marketing Authorisations  Anifrolumab is a monoclonal antibody that inhibits receptors for type I interferons. This immunosuppressant has been authorised in the European Union as add-­on therapy for patients with systemic lupus erythematosus in whom standard treatment has been insufficiently effective.
Full article (3 pages) available for download by subscribers

In this situation, two double-­blind randomised trials have evaluated anifrolumab versus placebo as an add-­on to standard immunosuppressant therapy, in a total of 822 patients who did not have severe renal or central nervous system involvement.

©Prescrire 1 May 2023

Source: "Anifrolumab (Saphnelo°) in systemic lupus erythematosus after failure of standard therapy" Prescrire International 2023; 32 (248): 117-119. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Read more:

All the subjects in
Prescrire's Spotlight
Free >